# BAT1308 Combined with Platinum-Based Chemotherapy± Bevacizumab for PDL1-Positive (CPS ≥1) Cervical Cancer

Source: https://onco.cc/trials/nct06123884/  
OnCo record `nct06123884` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2/3 trial of Cisplatin, Bevacizumab, Carboplatin in cervical cancer, run by Bio-Thera Solutions, now recruiting.

## Summary

BAT1308 Combined with Platinum-Based Chemotherapy± Bevacizumab for PDL1-Positive (CPS ≥1) Cervical Cancer is a phase 2/3 interventional study registered as NCT06123884 by Bio-Thera Solutions, with 526 participants planned, started 2023-12-13 and due to reach its primary completion in 2026-09. Interventions recorded: Recombinant humanized anti-PD-1 monoclonal antibody injection, Cisplatin, Bevacizumab Injection, carboplatin, Paclitaxel for Injection. Conditions listed: Cervical Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT06123884
- Phase: 2/3
- Setting: A Phase II/III Study to Evaluate the Safety and Efficacy of BAT1308 Combined with Platinum-Based Chemotherapy ± Bevacizumab As First-Line Therapy for PD-L1-Positive (CPS ≥ 1) Persistent, Recurrent or Metastatic Cervical Cancer
- Sponsor: Bio-Thera Solutions
- Enrolled: 526

## Sources

- ClinicalTrials.gov NCT06123884: https://clinicaltrials.gov/study/NCT06123884

## Connected records

- cancers: [Cervical cancer](https://onco.cc/cancers/cervical/)
- drugs: [Bevacizumab](https://onco.cc/drugs/bevacizumab/), [Carboplatin](https://onco.cc/drugs/carboplatin/), [Cisplatin](https://onco.cc/drugs/cisplatin/), [Paclitaxel / nab-paclitaxel](https://onco.cc/drugs/paclitaxel/)
- companies: [Bio-Thera Solutions](https://onco.cc/companies/bio-thera-solutions/)

---
JSON: https://onco.cc/api/v1/entities/nct06123884.json